Vitura Health (ASX:VIT) said that its revenue and earnings before interest, taxes, depreciation, and amortization increased successively during each of February, March, and April, according to a Monday Australian bourse filing.
The firm's focus on integrating the recently acquired Candor Medical business drove both revenue and EBITDA improvement, while the results for the March quarter included the inclusion of the first full quarter of contribution from the recently acquired Releaf Group, in which Vitura holds a 50% interest, demonstrating growth in patient numbers and revenue.
The firm is forecasting that the total revenue for the fourth quarter will support an annualized revenue rate over AU$138 million, a rise of 11% on the same figure for fiscal 2024.
It forecasts that EBITDA for the fourth quarter on an annualized basis should deliver the 3% improvement in EBITDA margin in fiscal 2025 the firm set out in the strategy reset. The firm expects the EBITDA figure for fiscal 2025 should increase by around 20%, as compared to the prior financial year.
The company's shares were up almost 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.